Biomedical subjects

A Tres Sánchez

Publications and source records attributed to A Tres Sánchez.

At least 19 recordsLinked to original sources

PubMed2000

[Value of nuclear medicine tests in oncology].

Explore the source record for details and available documents.

Adult↗

PubMed1992

[Medulloblastoma in the adult: presentation of a new case].

A case of hemispheric medulloblastoma of cerebellum in a 22 male patient is presented. The patient complained of headache and an intracranial hypertension syndrome progressively appeared. Diagnosis was established by CT scan. Treatment consisted of radical surgery associated to radiotherapy and chemotherapy. Present survival with this treatment is 4 years being the patient asymptomatic and without signs of relapse.

Adult↗

PubMed1992

[Effect of age, nutritional status and tumor extension on various immunologic parameters in cancer patients].

We studied cellular immune (total lymphocytes, lymphocytary populations and delay hypersensitivity skin tests) and humoral (immunoglobulins and complement) response, as well as nutritional status (anthropometric and biochemical para meters), antitumoral treatment. The effect of tumoral extension, nutritional status and age on immunity was assessed. We have demonstrated a poor relationship between the cellular immunological response and the extension of neoplasia, a moderate effect of age and a significant impact of nutritional status.

Age Factors↗

PubMed1991

[Primary lymphoma in the central nervous system treated with radiotherapy and chemotherapy. A case report].

A case of primary lymphoma of the central nervous system treated successfully with radiotherapy and systemic and intrathecal chemotherapy is described. The efficiency of the combination of radiotherapy with chemotherapy in the treatment of primary lymphoma of the central nervous system is discussed.

Brain Neoplasms↗

PubMed1990

[Antiemetic treatments associated with antineoplastic chemotherapy].

56 female patients with breast carcinoma and treated with polychemotherapy: adriamycin, vindesine, ciclophosphamide and 5-fluorouracil were studied, divided in three groups with different antiemetic schedule: group A 40 mg/iv of metoclopramide; group B 40 mg iv of metoclopramide and 125 mg/iv of methylprednisolone before beginning chemotherapy; and group C 2 mg/oral of lorazepam, 125 mg/iv methyl-prednisolone and 1 mg/kg/oral of metoclopramide previously to begin chemotherapy; at two and four hours of the first dose, metoclopramide was repeated the same doses (really) three doses each two hours. The combination of methylprednisolone-metoclopramide (B), decreases significantly the intensity, duration and frequency of nausea and vomiting, achieving total protection (no vomiting) in 4.34% of cycles of chemotherapy in group A, 32.2% in group B and 30.2% in group C (p less than 0.005 group A versus group B and A versus group C). Also we observed, without statistical analysis, better subjective tolerance to chemotherapy in patients receiving lorazepam associated to schedule B (schedule C). This makes it the recommended schedule.

Antiemetics↗

PubMed1990